Mesa Laboratories CFO John Sakys Sells Shares
John Sakys, CFO of Mesa Laboratories, sold 2,756 shares on June 18, 2026.
Key Points
- John Sakys, CFO of Mesa Laboratories, sold 2,756 shares on June 18, 2026.
- Shares of MLAB traded near $93.23 on Tuesday, with a market cap of $515 million and a P/E ratio of 77.05.
- Long Path Partners increased its stake in Mesa Laboratories by 178,360 shares, while BlackRock reduced its holdings by 4,815 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
John Sakys, the Chief Financial Officer of Mesa Laboratories, Inc., sold 2,756 shares of the company on June 18, 2026. This transaction was not part of a pre-arranged trading plan.
Insider Buying and Selling at Mesa Laboratories, Inc.
On June 18, 2026, John Sakys, CFO, sold 2,756 shares of Mesa Laboratories, Inc. Although the exact sale price wasn't disclosed, the transaction wasn't part of a pre-arranged 10b5-1 plan. On the same day, Brian David Archbold, the Senior Vice President of Operations, bought 1,859 shares at $95.10 each. Earlier, on June 22, 2026, Sakys sold another 2,827 shares at $89.50, while Archbold sold 2,516 shares at the same price.
Other Institutional Activity in Mesa Laboratories
Long Path Partners LP increased its holdings in Mesa Laboratories by 178,360 shares, bringing its total to 405,583 shares valued at approximately $35.86 million. BlackRock, Inc. trimmed its position by 4,815 shares, holding 393,851 shares worth about $34.82 million. Boston Partners added 55,335 shares, resulting in a total of 268,711 shares valued at $23.76 million. Select Equity Group, L.P. boosted its stake by 29,450 shares to 235,885 shares, with a value of $20.86 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 232,643 shares valued at $20.57 million.
Mesa Laboratories, Inc. Stock Down 27.7%
Shares of NasdaqGS:MLAB traded near $93.23 on Tuesday. Mesa Laboratories has a market capitalization of $515 million, with a P/E ratio of 77.05 and a forward P/E of 7.60. The stock's beta is 0.927, indicating less volatility compared to the market. Over the past 52 weeks, the stock has ranged from $55.45 to $113.99. Its 50-day moving average is $101.99, and the 200-day moving average is $84.97. The company maintains a current ratio of 1.72 and a quick ratio of 1.17, with a debt-to-equity ratio of 90.65.
$MLAB stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Mesa Laboratories reported revenue of $249.13 million, reflecting a growth rate of 2.6%. The company achieved a net margin of 2.69% and a return on equity of 3.88%. Earnings per share were $1.21. The next earnings release is scheduled for August 5, 2026.
Dividend
Mesa Laboratories pays an annual dividend of $0.64 per share, yielding 0.67%. The dividend payout ratio stands at 52.89%.
Analysts Set New Price Targets
On February 4, 2026, Wells Fargo maintained its 'hold' rating on Mesa Laboratories with a price target of $94. The consensus among analysts is a 'hold' rating, with an average price target of $112, based on two analyst opinions.
About Mesa Laboratories
Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, develops and sells life sciences tools and quality control products globally. It operates in sectors like sterilization and disinfection control, clinical genomics, biopharmaceutical development, and calibration solutions. The company provides various products, including sterilization indicators, genetic analysis tools, and protein analysis systems. Mesa Laboratories was founded in 1982 and is led by CEO Dr. Siddhartha Chandrakant Kadia.
Bottom Line
John Sakys' recent sale of Mesa Laboratories shares on June 18, 2026, is part of the ongoing insider activity at the company. Investors often track insider transactions to gauge executive sentiment. However, it's important to remember that these filings are historical and may not reflect current positions.
Get Mesa Laboratories, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MLAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.